BioSpace News Archive

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced that management will host a live webcast and conference call at 8:30 a.m. ET on Monday, May 11, 2020, to discuss its first quarter 2020 financial results and provide a business update..

Vanda Pharmaceuticals Inc. announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes.

Innoviva, Inc. (NASDAQ:INVA) (“Innoviva,” or “the Company”) today reported financial results for the first quarter ended March 31, 2020.

GlaxoSmithKline plc announced the US Food and Drug Administration approved the company’s supplemental New Drug Application for Zejula, an oral, once-daily poly polymerase inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial guidance for fiscal 2020.

Canadian Blood Services is proud to be part of CONCOR, a national clinical trial to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment to help patients infected with the virus.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority (BARDA) contract (“19C BARDA Contract”) worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox (tecovirimat).

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report the first quarter 2020 on Wednesday, May 6, 2020, after the close of the US market

4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™, announced today that following the company’s highest quarterly revenue to date in Q4 2019 it achieved its second highest quarterly revenue in the first quarter of 2020.

Sumitovant Biopharma Ltd. today announced that the journal Obstetrics & Gynecology has published three abstracts from Myovant Sciences detailing additional efficacy and safety findings from the Phase 3 LIBERTY 1 and 2 studies of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with heavy menstrual bleeding associated with uterine fibroids.